SynthesisBMC infectious diseases2025
Hepatitis B surface antigen seroprevalence in Morocco (2000-2024): a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Seroprevalence and Molecular Epidemiology of Hepatitis B and D Viruses in Mauritania: a Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B is a silently devastating disease that presents a public health concern and affects millions of people. Recent estimates indicate that 254 million individuals globally are afflicted with chronic HBV infection, with around 1.2 million new cases emerging annually and roughly 1.1 million fatalities primarily resulting from long-term consequences. Like other developing countries, Morocco still lacks consolidated epidemiological data on the real burden of hepatitis B. In this context, our work aims to fill this gap through a systematic review and a meta-analysis of studies conducted over the last 25 years.
methodsWe conducted a comprehensive search in databases such as PubMed, Scopus, Web of Science, and Google Scholar, focusing on studies related to Hepatitis B in Morocco. Our inclusion criteria encompass all observational studies conducted and published between 2000 and 2024 reporting HBsAg prevalence among individuals residing in Morocco regardless of age, sex, or subpopulations. The prevalence studies included were assessed using the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data. Where appropriate, a pooled prevalence was calculated using a DerSimonian-Laird random effects model.
results30 studies met the inclusion criteria, encompassing 34 cohorts and 750,784 individuals with prevalence ranging between 0.07% and 7.98%. HBsAg prevalence was assessed across four endemicity levels. About 74% of cohorts showed low prevalence (< 2%), seven studies lay in the 2-4.99% band. Only two studies reach the 5-7.99% band, while no study showed high endemicity (≥ 8%). The pooled prevalence of HBsAg in Morocco was 1.33% (95% CI: 1.07-1.61). Subgroup analysis revealed the lowest prevalence among military populations (0.36%) and the highest in vulnerable high-risk groups (5.43%), underscoring subpopulation-specific disparities in HBV burden.
conclusionsThe pooled prevalence observed across included studies reinforces the hypothesis that Morocco is transitioning towards a low-endemic HBV status, which reflects the comprehensive national measures, along with the positive impact of systematic vaccination of newborn introduced in 1999 and certain groups as well. However, additional efforts remain necessary to sustain this progress and adequately address the weaknesses observed at the national level in managing HBV infection, particularly among certain at-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.